The global molecular diagnostics industry was valued at USD 16.6 billion in 2024 and is projected to witness significant growth over the forecast period. The market is expected to surpass USD 43.4 billion by the end of 2035, expanding at a CAGR of 9.1% from 2025 to 2035. This growth is driven by the rising prevalence of infectious and genetic diseases, increasing demand for early and accurate diagnostic solutions, and continuous advancements in molecular testing technologies across clinical and research settings.

👉 Get sample market research report copy today @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783

Market Overview

The rising incidence of chronic and infectious diseases is expected to propel the growth of the molecular diagnostics market by increasing demand for quicker, more precise, and targeted diagnostic solutions. Infectious diseases that include COVID-19, HIV, Hepatitis, and respiratory infections require rapid detection to minimize the risk of transmission and initiate treatment at the earliest.

Molecular tests, for example, PCR testing, have become essential tools in response to public health emergencies. For instance, as per the data published by the Centers for Disease Control and Prevention in October 2024, 6 in 10 Americans are suffering from at least one chronic disease, and 4 in 10 have two or more of them. It further states that sexually transmitted infections (STIs) continue to rise in the United States, with over 2.5 million cases of gonorrhea, chlamydia, and syphilis in 2022

Analysts’ Viewpoint on the Molecular Diagnostics Market

The molecular diagnostics market is expanding at a rapid pace due to the rise in incidence of infectious diseases and cancer, along with the increasing frequency of genetic disorders, thereby resulting in an increased need for quick and precise diagnostics. Technological developments in PCR, liquid biopsy, next-generation sequencing (NGS), and point-of-care diagnostics are enhancing diagnostic efficiency and application areas, including advances in personalized medicine to cater to the market.

The global molecular diagnostics market has its limitations, including the capital cost of equipment and reagents, regulatory frameworks, reimbursement policies, and the fact that the developing parts of the world have limited skilled professionals.

Analysis of Key Players

The market is characterized by moderate consolidation, with the top five players controlling nearly 55% of global revenue.

Leading companies operating in the global market include:

• F. Hoffmann-La Roche AG
• Abbott
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company (BD)
• Illumina, Inc.
• bioMérieux
• DiaSorin S.p.A.
• Hologic, Inc.
• SD Biosensor, Inc.
• QIAGEN N.V.
• QuidelOrtho
• Siemens Healthineers AG
• Other Prominent Players

Recent Developments

• In April 2025, Abbott announced the launch of its CE-marked HR HPV assay in Europe. The newly launched diagnostic assay includes self-collection of vaginal samples using the simpli-COLLECT HPV Collection Kit or the Evalyn Brush. The test is approved for use by healthcare providers either alone or in combination with a Pap test and helps HCPs to perform risk assessment by identifying HPV genotypes 16, 18, and 45 while reporting the concurrent detection of the other high-risk genotypes.
• In September 2024, QIAGEN launched the QIAcuityDx Digital PCR System, a digital PCR tool for clinical diagnostics. The instrument and accessories are FDA-exempt in the U.S. and IVDR-certified for Europe. It offers precise quantitation of target DNA and RNA, thereby making it ideal for monitoring cancer progression. QIAGEN is expanding its application menu and partnering with pharmaceutical companies for companion diagnostics.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1783

Key Market Drivers

• Precision Oncology: The shift toward targeted therapies requires companion diagnostics (CDx) to identify specific genetic mutations before prescribing expensive drugs.
• Rising Burden of Infectious Disease: Emerging viral threats and the rise of antimicrobial resistance (AMR) are necessitating rapid, multiplexed diagnostic panels.
• Aging Global Population: The geriatric segment is more susceptible to chronic conditions like cancer and neurological disorders, fueling the demand for early-detection genetic screening.
• Non-Invasive Testing: The rise of Liquid Biopsies (testing via blood or urine) is replacing invasive tissue biopsies, significantly improving patient compliance and the frequency of monitoring.

Market Segmentation

➤ By Technology

• PCR: (Conventional, Real-time, and Digital PCR)
• Next-Generation Sequencing (NGS): (Fastest growth; crucial for rare diseases and cancer)
• Isothermal Amplification (INAAT): (Gaining share in POC due to lack of thermal cycling requirements)
• In Situ Hybridization (ISH): (Crucial for tissue-based cancer diagnosis)

➤ By Test Location

• Central Laboratories: (Maintains the largest share for high-volume routine testing)
• Point-of-Care (POC): (Expanding rapidly at 11.4% CAGR; includes clinics and pharmacies)
• Self-test / OTC: (Emerging niche for respiratory and reproductive health)

➤ By Region

• North America: (Largest market share ~42%; driven by high R&D spend and proactive regulatory environment)
• Asia-Pacific: (Fastest-growing region; 10.4% CAGR driven by government-funded genomics initiatives in China and India)
• Europe: (Strong focus on IVDR compliance and centralized universal healthcare screening

Conclusion

By 2035, the molecular diagnostics market will be defined by “Omnipresent Diagnostics.” The integration of AI with liquid biopsy and decentralized platforms will allow for continuous health monitoring rather than reactive sick-care. For stakeholders, the greatest opportunity lies in the transition toward Multi-Cancer Early Detection (MCED) and the automation of complex genomic data interpretation, making precision medicine accessible beyond high-tech facilities.

👉 To buy this comprehensive market research report, click here to inquire @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1783&ltype=S

FAQs

• How big was the global molecular diagnostics market in 2024?

The global molecular diagnostics market was valued at US$ 16.6 Bn in 2024

• What is the projected size of the molecular diagnostics industry by 2035?

The molecular diagnostics market is projected to cross US$ 43.4 Bn by the end of 2035

• What are the factors driving the molecular diagnostics market?

Rising prevalence of infectious and chronic diseases, technological advances in PCR, NGS, liquid biopsy & AI, and Expansion of Point-of-Care (POC) Testing

• How is the molecular diagnostics market expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 9.1% from 2025 to 2035

• Which region is expected to dominate the molecular diagnostics market during the forecast period?

North America is expected to account for the largest share from 2025 to 2035

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com